Search

Your search keyword '"Puoti, M"' showing total 47 results
Start Over Author "Puoti, M" Journal digestive & liver disease
47 results on '"Puoti, M"'

1. Hepatocellular Carcinoma in HIV-Infected Patients: Clinical Presentation and Outcomes.

Author

Alimenti, E., Monti, B., Peracchi, F., Fava, M., Colella, E., Columpsi, P., Squillace, N., Lapadula, G., Lampertico, P., Puoti, M., Bonfanti, P., Merli, M., Soria, A., De Silvestri, A., and Iavarone, M.

Abstract

Hepatocellular carcinoma (HCC) has become a non-AIDS complication with high impact on morbidity and mortality of people living with HIV (PLWH). We sought to compare outcomes in PLWH versus non-HIV-infected patients with cirrhosis treated for HCC in three hospitals in Lombardy. A retrospective analysis of prospectively followed patients diagnosed with HCC from 01/06/2006 to 15/04/2022 was performed. The clinical characteristics, access to treatment and survival of HIV-patients with HCC were described. Propensity score (PS) to address potential confounders due to unbalanced distribution of baseline characteristics was used to estimate the effect of HIV status on overall survival (OS) of PLWH. We identified 65 HIV patients with cirrhosis and first HCC diagnosis (median age 54 [44-73] years, 92% males, 63% HCV-pos, 73% Child-Pugh A, median CD4+ count 405 [44-1701] cells/mm3, 12.5% with previous AIDS diagnosis, median nadir CD4+ count 164.5 [11-750] cells/mm3) and 464 non-HIV patients (median age 68 [33-89] years, 75% male, 77% Child-Pugh A). In PLWH, HCC was single nodule in 55%, median size was 2.5 cm (1.0-6.3), 57% "Milan-in". BCLC stages were 55% 0/A, 13% B, 21% C and 11% D. 31 (50%) patients received first-line curative treatment. In non-HIV patients, HCC were single nodule in 57%, median size was 2.6 cm (0.5-18), 66% "Milan in". BCLC stages were 68% 0/A, 17% B, 14% C and 1% D; 284 (61%) patients received a first line curative treatment. Median follow up was 47 (0.2-175) months for PLWH and 30 (0.5-199) for non-HIV patients. For PLWH the 5-year overall survival rate was 58% compared to 56% for non-HIV (log rank p =0.61). HCC patients with HIV were more frequently male, younger, with multiple etiologies, poorer liver function and worse HCC stage at presentation. Nevertheless, PLWH have similar prognosis and access to HCC treatments as non-HIV patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

2. Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di).

Author

Anolli, M.P., Degasperi, E., D'Offizi, G., Brunetto, M.R., Verucchi, G., Federico, A., Ciancio, A., Mangia, A., Santantonio, T.A., Coppola, N., Pellicelli, A., Loglio, A., Viganò, M., Pileri, F., Maracci, Monia, Puoti, M., Piscaglia, F., and Lampertico, P.

Abstract

In phase II and III trials, Bulevirtide (BLV) significantly reduced HDV-RNA and aminotransferase (ALT) levels in patients with chronic hepatitis Delta virus (HDV) infection, however, data on efficacy and safety beyond week 48 in real-world settings are limited. HDV patients with compensated cirrhosis treated with BLV 2 mg monotherapy up to 72 weeks were retrospectively evaluated in this multicenter Italian real-life study. Clinical and virological variables were collected at baseline, weeks 4, 8 and every 8 weeks thereafter. 93 patients were included: median age 52 years, 52% males, liver stiffness measurement (LSM) 17.4 kPa, 55% with varices, 22% with previous ascites, 53% IFN-experienced, 97% under nucleos(t)ide (NUC) treatment. Median ALT levels were 79 U/L, albumin 3.9 g/dL, platelets 70 x 103/mm3, HDV RNA 5.2 Log IU/mL, CPT score A in all patients. A virological response (undetectable HDV RNA or ≥2 Log decline vs. baseline) was achieved by 67%, 77% and 75% of patients at weeks 24, 48 and 72, respectively, HDV RNA becoming undetectable in 10%, 16% and 38%. At the same timepoints, ALT normalization was observed in 67%, 67% and 81% of the patients while a combined response (virological + biochemical) was achieved by 45%, 56% and 63%. Besides ALT, significant on-treatment declines were also observed for AST, GGT, IgG (p<0.001 vs. baseline), while albumin values increased (p=0.02). Platelets, LSM and HBsAg levels remained unchanged. BLV was well tolerated, no patient discontinued treatment for adverse events, an asymptomatic increase in bile acids occurred in all patients. During BLV treatment, liver decompensation occurred in one patient, de-novo HCC in two, three underwent liver transplantation and one died for BLV-unrelated causes. Extension of BLV monotherapy to 72 weeks is safe and effective in patients with HDV-related compensated cirrhosis. Virological and clinical responses increase overtime. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

5. Alcohol and coffee drinking and smoking habit among subjects with HCV infection.

Author

Zani, C., Donato, F., Chiesa, M., Baiguera, C., Gelatti, U., Covolo, L., Antonini, M.G., Nasta, P., Gatti, F., Orizio, G., and Puoti, M.

Subjects
HEPATITIS C, COFFEE drinking, PHYSIOLOGICAL effects of tobacco, ALCOHOL drinking, SELF-report inventories, HEALTH behavior, STATISTICAL significance, PATIENTS
Abstract

Abstract: Background/aims: The aims were to estimate among patients with hepatitis C virus (HCV) infection the prevalence of alcohol and coffee intake and smoking habit, the reliability of these self-reported data and the possible change of patients’ habit after their first contact with a Viral Hepatitis Service. Methods: 229 patients were initially interviewed personally at the Viral Hepatitis Service and after 6 months they were re-interviewed by phone in regard to their alcohol, coffee drinking and smoking habits. Results: Alcohol drinkers were 55.5% of males and 35.3% of females. Most subjects drank coffee daily, both men (90.0%) and women (84.9%). The proportion of current smokers was higher in males (43.6%) than females (26.9%). We found a fair to good reliability of self-reported data regarding patients’ habits, alcohol and coffee intake, and number of cigarettes smoked daily. We observed a statistically significant decrease in alcohol and coffee intake and cigarettes smoked between baseline and follow-up interviews. Conclusion: We found a fairly high proportion of HCV-infected patients who regularly drink alcohol and coffee beverages and smoke cigarettes, especially among males. The reliability of self-reported data on these habits seems satisfactory. More decisive action to modify these habits, especially alcohol intake, is required in these patients. [Copyright &y& Elsevier]

Published
2009
Full Text
View/download PDF

6. The use of molecular assays in the management of viral hepatitis.

Author

Mangia, A., Antonucci, F., Brunetto, M., Capobianchi, M., Fagiuoli, S., Guido, M., Farci, P., Lampertico, P., Marzano, A., Niro, G., Pisani, G., Prati, D., Puoti, M., Raimondo, G., Santantonio, T., Smedile, A., and Lauria, F.

Subjects
VIRAL hepatitis, LIVER diseases, HEPATITIS C virus, HEPATITIS D virus
Abstract

Abstract: Molecular assays are instrumental in the clinical management of viral hepatitis. During the past years, a wide variety of molecular assays have been developed and implemented. This considerably improved the understanding of the natural history and pathogenesis of Hepatitis B virus (HBV), Hepatitis C virus (HCV) or Hepatitis delta virus (HDV) hepatitis, but also caused uncertainties in the selection of the most appropriate assays for clinical requirements. Indeed, a rational choice and application of these assays requires adequate knowledge of the performance of the single test. Moreover, the choice of the most accurate assay for patients’ needs and physicians’ objectives, needs to be oriented to specific contexts, such as diagnosis, management or treatment. In the past, a hurdle in the routine use of assays for hepatitis viruses nucleic acid quantification was represented by the availability of only “home brew” methods which lacked standardization. Major improvement in addressing the use of molecular assays for viral hepatitis has been derived from recent standardization procedures that allowed a comparison between different tests after results were given as International Units. In addition, it should be reminded that, before getting into the market, molecular assays should be approved by European regulation authorities and validated using internationally recognized standards. A subsequent clinical validation should address the diagnostic accuracy of the assay. These proceedings have the aim of identifying which molecular tests, among those currently available, meet clinical requirements for each specific application. [Copyright &y& Elsevier]

Published
2008
Full Text
View/download PDF

7. Prophylaxis and treatment of hepatitis B in immunocompromised patients.

Author

Marzano, A., Angelucci, E., Andreone, P., Brunetto, M., Bruno, R., Burra, P., Caraceni, P., Daniele, B., Di Marco, V., Fabrizi, F., Fagiuoli, S., Grossi, P., Lampertico, P., Meliconi, R., Mangia, A., Puoti, M., Raimondo, G., and Smedile, A.

Subjects
HEPATITIS B treatment, VIRAL hepatitis, IMMUNOSUPPRESSIVE agents, ANTIVIRAL agents
Abstract

Abstract: The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and referred mainly to the pre-antivirals era. Today a rational approach to the problem of hepatitis B in these patients provides for: (a) the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline), (b) the treatment with antivirals (therapy) of active carriers, (c) the pre-emptive use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, (d) the biochemical and hepatitis B surface antigen (HBsAg) monitoring (or universal prophylaxis, in case of high risk immunosuppression) in subjects with markers of previous contact with HBV (HBsAg negative and anti-HBc positive), in order to prevent reverse seroconversion. Moreover it is suggested a strict adherence to criteria of allocation based on the virological characteristics of both recipients and donors in the general setting of transplants and in liver transplantation the universal prophylaxis with nucleos(t)ides analogues (frequently combined with specific anti-HBV immunoglobulins) in HBsAg positive candidates and in HBsAg negative recipients of anti-HBc positive grafts. [Copyright &y& Elsevier]

Published
2007
Full Text
View/download PDF

10. Forecasting liver disease burden.

Author

Robbins, S., Kondili, L.A., Blach, S., Gamkrelidze, I., Zignego, A.L., Brunetto, M.R., Raimondo, G., Taliani, G., Iannone, A., Russo, F.P., Santantonio, T., Zuin, M., Chessa, L., Blanc, P.L., Puoti, M., Vinci, M., Erne, E.M., Strazzabosco, M., Massari, M., and Lampertico, P.

Published
2018
Full Text
View/download PDF

11. Impaired renal function but high sustained virological response (SVR) rates in hepatitis C virus (HCV) elderly treated with direct-acting antivirals (DAA): A report from the Lombardy Network.

Author

D’Ambrosio, R., Pasulo, L., Aghemo, A., Puoti, M., Zaltron, S., Maggiolo, F., Rizzardini, G., Fargion, S., Sacchi, P., Gulminetti, R., Zuin, M., Quirino, T., Rumi, M.G., Pan, A., Grossi, P., Rossini, A., Corbellini, A., Foppa, C. Uberti, Colli, A., and Lampertico, P.

Published
2018
Full Text
View/download PDF

14. Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto Networks.

Author

Degasperi, E., Spinetti, A., Lombardi, A., Landonio, S., Scotton, P., Pasulo, L., Carlotto, A., Giorgini, A., Pozzoni, P., Angeli, P., Carrara, M., Puoti, M., Gatti, F., Carolo, G., Vinci, M., Zoncada, A., Bonfanti, P., Aghemo, A., Soria, A., and Centenaro, R.

Published
2019
Full Text
View/download PDF

15. Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study Group.

Author

Degasperi, E., Pasulo, L., Aghemo, A., Puoti, M., Zaltron, S., Maggiolo, F., Rizzardini, G., Fargion, S., Sacchi, P., Gulminetti, R., Zuin, M., Quirino, T., Rumi, M.G., Pan, A., Grossi, P., Rossini, A., Corbellini, A., Uberti Foppa, C., Colli, A., and Piovesan, S.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results